Viewing Study NCT06560528


Ignite Creation Date: 2025-12-26 @ 10:32 AM
Ignite Modification Date: 2025-12-26 @ 10:32 AM
Study NCT ID: NCT06560528
Status: RECRUITING
Last Update Posted: 2024-08-19
First Post: 2024-08-15
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module